| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Siratzki Chair of Neurology (Dr. Korczyn), Tel Aviv University, Israel; the Department of Neurology (Dr. Brunt), University Hospital Groningen, the Netherlands; the Neurology Department (Dr. Larsen), Central Hospital of Rogaland, Stavanger, Norway; the National Stroke Centre (Dr. Nagy), Budapest, Hungary; the Department of Neurology (Dr. Poewe), University of Innsbruck, Austria; and the Department of Neurological Sciences (Dr. Ruggieri), University "La Sapienza," Rome, Italy.
Address correspondence and reprint requests to Professor Amos D. Korczyn, Department of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel; e-mail: neuro13{at}ccsg.tau.ac.il
OBJECTIVE: To compare the long-term efficacy and safety of ropinirole with bromocriptine over 3 years in patients with early PD with limited or no previous dopaminergic therapy.
METHODS: In this prospective, double-blind, parallel-group study, 335 patients were randomized to 0.75 mg ropinirole or 1.25 mg bromocriptine titrated upward at weekly intervals—maximum permitted daily doses were 24 mg ropinirole, 40 mg bromocriptine.
RESULTS: Approximately one third of patients in each group withdrew prematurely, mostly because of adverse experiences; 61/102 (60%) of ropinirole-treated and 59/112 (53%) of bromocriptine-treated patients completed the study on the dopamine agonist alone. Mean doses for all patients at completion were 12 mg (SD 6) ropinirole and 24 mg (SD 8) bromocriptine. Occurrence of adverse experiences in both groups was similar. Emergence of dyskinesias was low. Both treatments induced marked improvements in Unified Parkinson’s Disease Rating Scale activities of daily living (ADL, Part II) and motor (Part III) scores over the first 12 weeks, which were maintained during the study. After 3 years, patients in the ropinirole group had a mean improvement in motor score of 31% compared with 22% in the bromocriptine group (p = 0.086) and a significantly better ADL score (treatment difference 1.46 points, p = 0.029).
CONCLUSIONS: Both dopamine agonists are effective in the early treatment of a high proportion of PD patients; effectiveness persists for at least 3 years. Those who completed the study had a significantly better functional status on ropinirole than on bromocriptine.
This article has been cited by other articles:
|
|
 |
|
  J. J. Chen and R. Pahwa Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease Journal of Pharmacy Practice, August 1, 2008; 21(4): 244 - 253. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Pahwa, M. A. Stacy, S. A. Factor, K. E. Lyons, F. Stocchi, B. P. Hersh, L. W. Elmer, D. D. Truong, N. L. Earl, and on behalf of the EASE-PD Adjunct Study Investigato Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease Neurology, April 3, 2007; 68(14): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Guimaraes, K. Kieburtz, C. G Goetz, J. J Elm, Y. Y Palesch, P. Huang, B. Ravina, C. M Tanner, and B. C Tilley Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials Clinical Trials, December 1, 2005; 2(6): 509 - 518. [Abstract] [PDF]
|
|
|
|
 |
|
 R Bhidayasiri Differential diagnosis of common tremor syndromes Postgrad. Med. J., December 1, 2005; 81(962): 756 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Nicholson, A. C. Pereira, and G. M. Hall Parkinson's disease and anaesthesia Br. J. Anaesth., December 1, 2002; 89(6): 904 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Holloway and A. W. Dick Clinical trial end points: On the road to nowhere? Neurology, March 12, 2002; 58(5): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lees, R. Katzenschlager, J. Head, and Y. Ben-Shlomo Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial Neurology, November 13, 2001; 57(9): 1687 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J BROOKS Dopamine agonists: their role in the treatment of Parkinson's disease J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 685 - 689. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, A. E. Lang, and The 056 Study Group A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa N. Engl. J. Med., May 18, 2000; 342(20): 1484 - 1491. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
